Search

Background: Treatment with medical cannabis (MC) in the United States tends to be patient-driven in nature despite evidence that suggests that patients have remarkably poor knowledge on the medical use of this treatment modality.Objective: To develop and pilot a collaborative, fee-for-service (FFS), office-based, pharmacist-directed MC therapy management (MCTM) service for patients suffering chronic pain.Practice Description: A collaborative, FFS, office-based, pharmacist-directed MCTM service where patients are seen after a physician deems them suitable for treatment with MC. The pharmacist designs the initial treatment regimen by selecting a formulation, dose, route, and frequency of administration and then manages ongoing therapy by making regimen changes based on the patient's response, adverse effects, and financial concerns.Practice Innovation: The creation of a specialized service where a registered MC pharmacist is positioned in a collaborating provider's office and sees patients face-to-face for the provision of MCTM services.Evaluation Methods: Patient retention, revenue generated, and ability to replicate the service were evaluated. Patient satisfaction was assessed by collecting subjective feedback on the service.Results: The pilot site that developed the service has seen 133 patients from 2016 to 2021 and has retained 89% of patients after 5 years of quarterly appointments. Patients appear willing to pay out of pocket for the service, and the revenue generated covers the pharmacist's and collaborating physician's time as well as additional overhead. The service has been replicated at 2 additional sites, and patient feedback has been positive.Conclusions: MCTM is another useful pharmacist service that patients are willing to pay for. MCTM services decrease the collaborating provider's workload while still allowing them to offer their patients personalized treatment with MC. In our experience, the service retains patients, generates enough revenue to cover costs, can be replicated, and is well received by patients. [ABSTRACT FROM AUTHOR]

The article highlights the life of LaDonna Harris, a Native American woman who was active in advocating for her people's rights in the U.S. during the 1960s. A background on her childhood as a Comanche is presented, emphasizing on the social conditions during the time. Harris' involvement with the civil rights movement with her husband are highlighted. Noting Harris' experience as an advocate, the article also discusses stereotypes against Native Americans.

The American Board of Psychiatry and Neurology was formed in 1934, and the first certifying examination was administered in 1935. It was not until 1969 that the American Board of Psychiatry and Neurology began conducting certifying examinations in child neurology. Since then, 10 child neurologists have served as American Board of Psychiatry and Neurology directors and nearly 1500 child neurologists have been certified, more than 200 of whom have also attained certification in the subspecialties of clinical neurophysiology, neurodevelopmental disabilities, and pain medicine. This article describes the evolution of the certification process as the Board has endeavored to use the best testing methodologies to fulfill its commitment to the public and to its constituents in psychiatry and neurology. Training pathways in child neurology are also reviewed as they have evolved in response to evident staff shortages and to promote entry into academic careers.